611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Medical Disorders
Resources
Basic InformationLookupsLatest News
AHA News: Lovely But Dangerous, Wood Fires Bring Health Risks'Prehab' Before Surgery Helps Speed Seniors' RecoveryFlu Cases Are Spiking Early, Suggesting Tough Season AheadHealth Tip: Remedies for ConstipationAs Cases of Vaping-Linked Illness Rise, CDC Points to Certain Brands as CulpritsAHA News: Could Fish Oil Fight Inflammation?One Boy's Battle Back From Mysterious Polio-Like IllnessHealth Tip: Advice on Home Wound CareOver 40% of Antibiotics Could Be 'Inappropriately' PrescribedRural Seniors Hurt by Lack of Medical SpecialistsHealth Tip: Understanding Muscle SpasmsBlack Patients May Not Gain Heart Benefit From Low-Dose AspirinIs Pot Use a Heart Risk After Surgery?E. Coli Outbreak Spurs Packaged Salad WarningHealth Tip: Should I Get a Cholesterol Test?Are Superbugs Making Themselves at Home in Your Makeup Bag?Sometimes, Aspirin May Be Enough to Ease MigrainesDangers of 'Superbug' Germs Greater Than BelievedAdditives to E-Cigarettes May Be Upping Health DangersMany Kids Traveling Overseas Aren't Vaccinated Against MeaslesVirtual Doc Visits Suffice for Many With Neurological DisordersBPA Levels in Humans Are Underestimated: StudyCleaner Air Quickly Brings Big Health Benefits, Study FindsAll 50 States Now Reporting Cases of Severe Vaping-Linked Lung Injury3 Drugs for Severe Epileptic Seizures Are Equally Effective: StudyStudy Casts Doubt on Use of Common Heart Failure Drugs'Mobile Stroke Units' Help Rush Treatment to PatientsDistracted by Their Smartphones, Pedestrians Are Landing in the ERVaping May Have Triggered Lung Illness Typically Only Seen in MetalworkersMore Than 100 E. Coli Illnesses Now Linked to Romaine LettuceLow-Dose Aspirin Might Cut Cancer Risk, Especially for Overweight PeopleEspecially in the Young, Cholesterol Is No Friend to the HeartAre E-Scooters a Quick Ticket to the ER?Uncontrolled Asthma a Danger to Pregnant Women, BabiesHealth Tip: Common Causes of Knee PainSome Cities' Smog Can Ruin Your VacationParkinson's Treatment Has Unexpected Side EffectHeart Attack at 44 Helped Her Realize Diabetes' DangersCleaner Teeth, Healthier Heart?Obesity Might Weaken Some Drugs' Effectiveness Against AFibHow to Prevent Holiday HeadachesAir Pollution May Up Glaucoma RiskHealth Tip: Causes of Stomach UlcersHealth Tip: Treating ShinglesLeg Pain Could Spell Peripheral Artery Disease for SomeEven in Small Doses, Air Pollution Harms Older AmericansDon't Let Allergies Spoil Your HolidaysGot Chronic Heartburn? Easy Does It During the Thanksgiving FeastAHA News: Flu Prevention Strategies Beyond Getting a Shot and Washing Your HandsUltrasound Treatment Might Ease Parkinson's Tremors
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

FDA Approves Oxbryta for Treatment of Sickle Cell Disease


HealthDay News
Updated: Nov 26th 2019

new article illustration

TUESDAY, Nov. 26, 2019 (HealthDay News) -- Oxbryta (voxelotor) has been granted accelerated approval for the treatment of sickle cell disease in patients ages 12 years and older, the U.S. Food and Drug Administration announced Monday.

Oxbryta is the first approved treatment for sickle cell disease that directly inhibits the root cause of the disease, sickle hemoglobin polymerization, according to a company press release. Nonclinical studies of Oxbryta have shown the drug inhibits red blood cell sickling and improves red blood cell deformability and the ability of blood to flow. The recommended dosage of Oxbryta is 1,500 mg orally once daily with or without food. For severe hepatic impairment, the recommended dosage is 1,000 mg orally once daily.

Approval of Oxbryta was based on clinical data from the HOPE Study of 274 patients with sickle cell disease who received 1,500 or 900 mg of Oxbryta (90 and 92 patients, respectively) or placebo (92 patients). After 24 weeks of treatment, 51.1 percent of patients who received 1,500 mg of Oxbryta achieved an increase of greater than 1 g/dL in hemoglobin response rate compared with 6.5 percent of patients who received placebo.

Commonly reported side effects with Oxbryta include headache, diarrhea, abdominal pain, nausea, fatigue, rash, and fever.

Approval was granted to Global Blood Therapeutics. The drug is expected to be available through a specialty pharmacy partner network within two weeks.

More Information